OpenFederal grantOpen to for-profit businessesPAR-25-069

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

National Institutes of HealthCloses Jan 7, 2027(86 days left)

Does this fit your business?

This is an NIH R01 research grant for scientists studying how GLP-1/GIP drugs (incretin mimetics) affect cancer risk, through preclinical or patient-based studies. It is for organizations that can run serious biomedical research, not for businesses looking for general operating money. If you are not doing cancer or metabolic-disease research, do not apply.

Best for
Universities and academic research teams, Nonprofits with biomedical research programs, Small biotech and for-profit research firms, Tribal and government entities running health research
Not for
Businesses with no research capability, Organizations wanting funding for treatment or services rather than research, Applicants expecting a published award amount or set-aside
Estimated fit by industry, best first
IndustryEstimated fit
Healthcare & BiotechMatches your industry (clinical)
65
Good Match
Energy & Clean TechLimit: Nothing in this notice points to energy & clean tech
54
Possible Match
Environment & ConservationLimit: Nothing in this notice points to environment & conservation
54
Possible Match
Technology & SoftwareLimit: Nothing in this notice points to technology & software
53
Possible Match
Education & TrainingLimit: Nothing in this notice points to education & training
52
Possible Match
Arts & CultureLimit: Nothing in this notice points to arts & culture
50
Possible Match
Show all 15 industries
Estimated fit by industry, best first
IndustryEstimated fit
Housing & Real EstateLimit: Nothing in this notice points to housing & real estate
50
Possible Match
Agriculture & FarmingLimit: Nothing in this notice points to agriculture & farming
49
Possible Match
Construction & InfrastructureLimit: Nothing in this notice points to construction & infrastructure
49
Possible Match
Finance & BankingLimit: Nothing in this notice points to finance & banking
49
Possible Match
Food & BeverageLimit: Nothing in this notice points to food & beverage
49
Possible Match
ManufacturingLimit: Nothing in this notice points to manufacturing
49
Possible Match
Retail & E-CommerceLimit: Nothing in this notice points to retail & e-commerce
49
Possible Match
Social Services & NonprofitLimit: Nothing in this notice points to social services & nonprofit
49
Possible Match
Transportation & LogisticsLimit: Nothing in this notice points to transportation & logistics
49
Possible Match

These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.

What this funds

Money can be used for
Research
Who can apply
Small businesses, For-profit companies, Nonprofits, State and local governments, Tribal governments and organizations, Colleges and universities, Other applicants (see eligibility)

Questions about this grant

When is the application deadline?
January 7, 2027.
Who can apply for this grant?
Universities (public, state-controlled, and private), nonprofits with or without 501(c)(3) status, small businesses and other for-profit organizations, state, county, city, township, special district, and independent school district governments, public and Indian housing authorities, federally recognized and other Native American tribal governments and organizations, and certain other entities named in the eligibility text, including some foreign organizations. NIH runs the program.
Can a sole proprietor or single-member LLC apply?
The facts do not say. Small businesses are listed as eligible, but the notice does not spell out whether a sole proprietor or single-member LLC qualifies, so check the full announcement on Grants.gov before counting on it.
Can a nonprofit apply?
Yes. Nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status (other than institutions of higher education) are both listed as eligible applicants.

Summary

NIH R01 research grants for preclinical and patient-based studies on how incretin mimetics (GLP-1/GIP agents) affect cancer risk. Open to universities, nonprofits, small and other for-profit businesses, state/local/tribal governments, and some foreign entities.

About this grant

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Who can apply

Other Eligible Applicants include the following:

Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Topics and uses of funds

Topics

  • Health
  • Science

Program contact

National Institutes of Healthgrantsinfo@nih.gov301-402-2541

Related grants

Open opportunities funding similar work, from the same funder or in the same place.

All grantsGrants by stateGrants by industry